Big Pharma Eyes Next Childhood Vaccine Cash Cow — mRNA Vaccines for RSV
Now that COVID vaccines have established mRNA technology as the “new frontier for vaccine development,” pharma giants have set their sights on an mRNA vaccine for respiratory syncytial virus (RSV) — which they hope to add to an already overburdened childhood vaccine schedule.
The Defender is experiencing censorship on many social channels. Be sure to stay in touch with the news that matters by subscribing to our top news of the day. It's free.
Over the decades since childhood vaccines began rolling out on a widespread scale, pediatric vaccine injuries have left many parents regretful for forgetting or ignoring a basic history lesson.
That lesson, in the words of Harvard medical historian David Jones, is that “when it comes to vaccines and immunization … there always has been a risk and there always will be a risk.”
Sixty-five years ago, families learned about the risks of medical experimentation the hard way when they allowed researchers to use their infants as test subjects …